Inhibrx price target lowered to $27 from $35 at JMP Securities

JMP Securities analyst Reni Benjamin lowered the firm’s price target on Inhibrx to $27 from $35 and keeps an Outperform rating on the shares. The firm believes shares are attractively valued with four distinct assets in the clinic, a registrational trial for INBRX-101 enrolling patients, results from multiple studies expected over the next 6-12 months, and a cash position of $192.5M, the analyst tells investors in a research note.